At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 81 enrolled
Drug / intervention
Ofatumumabdrug
Likely dose
Ofatumumab 300mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Single-arm. Multi-center Phase 2 Trial With Ofatumumab in Patients With Relapsed/Progressive Diffuse Large B-Cell Lymphoma (DLBCL) Ineligible for Transplant or Relapse/Progression After Autologous Transplant
In Brief
A Phase 2 clinical trial evaluating Ofatumumab for Lymphoma, Large-Cell, Diffuse. Completed, enrolled 81 participants across 1 site.
Detailed Summary
The purpose of this trial is to determine the effect of ofatumumab in patients with Diffused Large B-Cell Lymphoma (DLBCL) ineligible for transplant or relapsed after autologous transplant
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphoma, Large-Cell, Diffuse
CountriesUnited Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 2007
First PostedFeb 2008
Primary CompletionMay 2010
Study CompletionAug 2014
TodayJul 2026
First PostedFeb 25, 2008
Enrollment StartDec 1, 2007
Primary CompletionMay 1, 2010
Study CompletionAug 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 18.4 years ago
Interventions
Ofatumumabdrug
8 weekly intra-venous (i.v.) infusions, 1 x 300mg and 7 x 1000mg